Optimized management of advanced hepatocellular carcinoma: Four long-lasting responses to sorafenib

Giovanni Abbadessa, Lorenza Rimassa, Tiziana Pressiani, Cynthia Carrillo-Infante, Emanuele Cucchi, Armando Santoro

Research output: Contribution to journalArticlepeer-review


The therapeutic options for hepatocellular carcinoma (HCC) have been so far rather inadequate. Sorafenib has shown an overall survival benefit and has become the new standard of care for advanced HCC. Nevertheless, in clinical practice, some patients are discontinuing this drug because of side effects, and misinterpretation of radiographic response may contribute to this. We highlight the importance of prolonged sorafenib administration, even at reduced dose, and of qualitative and careful radiographic evaluation. We observed two partial and two complete responses, one histologically confirmed, with progression-free survival ranging from 12 to 62 mo. Three of the responses were achieved following substantial dose reductions, and a gradual change in lesion density preceded or paralleled tumor shrinkage, as seen by computed tomography. This report supports the feasibility of dose adjustments to allow prolonged administration of sorafenib, and highlights the need for new imaging criteria for a more appropriate characterization of response in HCC.

Original languageEnglish
Pages (from-to)2450-2453
Number of pages4
JournalWorld Journal of Gastroenterology
Issue number19
Publication statusPublished - May 21 2011


  • Decision making
  • Drug toxicity
  • Hepatocellular carcinoma
  • Response criteria
  • Sorafenib

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Optimized management of advanced hepatocellular carcinoma: Four long-lasting responses to sorafenib'. Together they form a unique fingerprint.

Cite this